Beta-blocker benefit according to severity of heart failure
- PMID: 12798825
- DOI: 10.1016/s1388-9842(03)00042-4
Beta-blocker benefit according to severity of heart failure
Abstract
Background and aims: Beta-blockers are an established treatment for chronic heart failure. However, the relationship between their benefit and the severity of the disease remains to be determined.
Methods and results: We studied the relationship between amplitude of benefit of beta-blockers and severity of chronic heart failure, based on data for mortality and hospitalizations for worsening heart failure, using a meta-analysis of randomized controlled trials, complementary subgroup analyses and analysis of individual data from the CIBIS II trial. In the meta-analysis, mortality was reduced by 22% (95%CI: 16 to 28) and hospitalizations for worsening heart failure by 24% (95%CI: 20 to 29). Benefit was similar with metoprolol, bisoprolol and carvedilol. After exclusion of bucindolol trials, due to the heterogeneity of results for mortality, the reduction in mortality was similar according to the severity of heart failure, assessed either by left ventricular ejection fraction or by New York Heart Association classification. In CIBIS II, beta-blockers induced a significant reduction in mortality of 45% (95%CI: 9 to 66), 41% (95%CI: 17 to 59) and 23% (95%CI: 1 to 40) in the low, intermediate and high risk groups, respectively. Hospitalizations were reduced by 35% (95%CI: 2 to 57), 41% (95%CI: 18 to 58) and 23% (95%CI: 0 to 41), there was no significant difference between the three score groups.
Conclusion: We conclude that the amplitude of benefit of the beta-blockers carvedilol, metoprolol and bisoprolol on mortality and morbidity is similar, regardless of the severity of chronic heart failure.
Similar articles
-
Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.J Am Coll Cardiol. 2010 Apr 27;55(17):1780-7. doi: 10.1016/j.jacc.2010.01.024. J Am Coll Cardiol. 2010. PMID: 20413026 Clinical Trial.
-
Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure.Clin Res Cardiol. 2017 Sep;106(9):711-721. doi: 10.1007/s00392-017-1115-0. Epub 2017 Apr 22. Clin Res Cardiol. 2017. PMID: 28434020
-
The large-scale placebo-controlled beta-blocker studies in systolic heart failure revisited: results from CIBIS-II, COPERNICUS and SENIORS-SHF compared with stratified subsets from MERIT-HF.J Intern Med. 2014 Feb;275(2):134-43. doi: 10.1111/joim.12141. Epub 2013 Oct 24. J Intern Med. 2014. PMID: 24118421
-
Beta-blockers to reduce mortality in patients with systolic dysfunction: a meta-analysis.J Fam Pract. 2001 Jun;50(6):499-504. J Fam Pract. 2001. PMID: 11401736
-
Use of beta-blockers in congestive heart failure.Ann Med. 2003;35(4):259-66. doi: 10.1080/14734220310011716. Ann Med. 2003. PMID: 12846268 Review.
Cited by
-
Dynamics of adrenergic signaling in cardiac myocytes and implications for pharmacological treatment.J Theor Biol. 2021 Jun 21;519:110619. doi: 10.1016/j.jtbi.2021.110619. Epub 2021 Mar 16. J Theor Biol. 2021. PMID: 33740423 Free PMC article.
-
Treatment of heart failure in Dutch general practice.BMC Fam Pract. 2006 Jul 5;7:40. doi: 10.1186/1471-2296-7-40. BMC Fam Pract. 2006. PMID: 16822303 Free PMC article.
-
Bucindolol: a pharmacogenomic perspective on its use in chronic heart failure.Clin Med Insights Cardiol. 2011;5:55-66. doi: 10.4137/CMC.S4309. Epub 2011 Jun 28. Clin Med Insights Cardiol. 2011. PMID: 21792345 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical